×
Zoetis Inventory 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis inventory for the quarter ending December 31, 2024 was
$2.306B
, a
10.06% decline
year-over-year.
Zoetis inventory for 2024 was
$2.306B
, a
10.06% decline
from 2023.
Zoetis inventory for 2023 was
$2.564B
, a
9.34% increase
from 2022.
Zoetis inventory for 2022 was
$2.345B
, a
21.94% increase
from 2021.
View More
Zoetis Inventory 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis inventory for 2024 was
$2.306B
, a
10.06% decline
from 2023.
Zoetis inventory for 2023 was
$2.564B
, a
9.34% increase
from 2022.
Zoetis inventory for 2022 was
$2.345B
, a
21.94% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$79.9B
Daiichi Sankyo, - (DSNKY)
$43.9B
Takeda Pharmaceutical (TAK)
$43.7B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.3B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$17B
Summit Therapeutics (SMMT)
$15.9B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.4B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Orion OYJ (ORINY)
$7.4B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Grifols, S.A (GRFS)
$5.1B
Ionis Pharmaceuticals (IONS)
$5B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4.2B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Hypermarcas (HYPMY)
$2.2B
Centessa Pharmaceuticals (CNTA)
$2.1B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Ardelyx (ARDX)
$1.5B
Indivior (INDV)
$1.5B